Cargando…

Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement

Evaluation of early response by flow cytometry and immunogloblin heavy chain assessments against primary bone marrow B‐cell lymphoma could be valuable for predicting treatment outcome.

Detalles Bibliográficos
Autores principales:	Nabe, Yoshimi, Kikuchi, Shohei, Kamihara, Yusuke, Wada, Akinori, Murakami, Jun, Sato, Tsutomu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365553/ https://www.ncbi.nlm.nih.gov/pubmed/34430019 http://dx.doi.org/10.1002/ccr3.4657

Ejemplares similares

Involvement of activation induced cytidine deaminase in malignant B-cells expressing two distinct M-components as an etiology of biclonal gammopathy
por: Kikuchi, Shohei, et al.
Publicado: (2022)

A Novel Mechanism for Bone Loss: Platelet Count Negatively Correlates with Bone Mineral Density via Megakaryocyte-Derived RANKL
por: Kikuchi, Shohei, et al.
Publicado: (2023)

Tumor-to-tumor metastasis of diffuse large B cell lymphoma to gastric adenocarcinoma via CXCL12 (SDF-1)/CXCR4 axis: a case report
por: Kamihara, Yusuke, et al.
Publicado: (2021)

Tozinameran: Immunogloblin A nephropathy, fever and headache: case report
Publicado: (2022)

Protein-losing Enteropathy Complicated with Primary Intestinal Follicular Lymphoma
por: Minemura, Tomoki, et al.
Publicado: (2021)

DPP8 Selective Inhibitor Tominostat as a Novel and Broad-Spectrum Anticancer Agent against Hematological Malignancies
por: Kikuchi, Shohei, et al.
Publicado: (2023)

Rituximab Administration and Reactivation of HBV
por: Tsutsumi, Yutaka, et al.
Publicado: (2010)

Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer
por: Yasuda, Manabu, et al.
Publicado: (2022)

Tu1553: SPECIFIC IMMUNOGLOBLIN A INDUCED BY THE PERSISTENT COLONIZATION OF ADHERENT-INVASIVE E.COLI LIMITS PATHOBINT LOCALIZATION TO THE EPITHELIAL NICHE
por: Imai, Jin, et al.
Publicado: (2022)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
por: Wei, Xiaolei, et al.
Publicado: (2014)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
por: de Jonge, A. Vera, et al.
Publicado: (2023)

Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
por: Li, Xueying, et al.
Publicado: (2019)

Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies
por: Kobayashi, Eiji, et al.
Publicado: (2023)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
por: Claustre, Gwladys, et al.
Publicado: (2022)

Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis
por: Hong, Junshik, et al.
Publicado: (2010)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent
por: Sekiguchi, Naohiro, et al.
Publicado: (2018)

Rituximab-CHOP Induced Interstitial Pneumonitis in Patients with Disseminated Extranodal Marginal Zone B Cell Lymphoma
por: Kim, Kwang Min, et al.
Publicado: (2008)

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
por: Lisenko, K., et al.
Publicado: (2017)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Monoclonal immunoglobulin heavy chain gene rearrangement in Fuchs’ uveitis
por: Nakahara, Hisae, et al.
Publicado: (2018)

Immunoglobulin Heavy Chain Gene Rearrangements in Patients with Gaucher Disease
por: Rodić, Predrag, et al.
Publicado: (2018)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System
por: Cabrera, María Elena, et al.
Publicado: (2022)

A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy
por: Kim, Kyung Min, et al.
Publicado: (2009)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
por: Choi, Yong Won, et al.
Publicado: (2014)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
por: Cho, Kyoung Min, et al.
Publicado: (2019)

Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes
por: Liu, Shu, et al.
Publicado: (2021)

Autologous bone marrow transplantation in patients relapsed one year after R-CHOP?
por: Pereira, Juliana
Publicado: (2012)

Tyrosine kinase inhibitor and rituximab‐CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report
por: Takeyasu, Yuki, et al.
Publicado: (2017)

What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness
por: Sekiguchi, Naohiro, et al.
Publicado: (2019)

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
por: Nakayama, Takafumi, et al.
Publicado: (2020)

Immunophenotyping of Peripheral Blood and Bone Marrow Cells by Flow Cytometry
por: Akanni, EO, et al.
Publicado: (2006)

Mass cytometry staining for human bone marrow clinical samples
por: Hallisey, Margaret, et al.
Publicado: (2022)

Immunoglobulin heavy chain gene rearrangement in heavy chain deposition disease suggests it is a plasma cell disease: a case report
por: Rao, Qingqing, et al.
Publicado: (2022)

Better method for detection of CD30: Immunohistochemistry or flow cytometry?
por: Higashi, Morihiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e5euiphgf8hussrkrjbpqlna34